is semaglutide as effective as tirzepatide Why a better option than for weight loss Comparative safety and side effects

Approved by the Central Drugs Standard Control Organization (CDSCO), Mounjaro is the first dual-target therapy that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, helping regulate blood sugar levels while promoting weight loss

Major studies leading to the approval of naltrexone/bupropion reported an average placebo-subtracted weight loss of 3.7% at a dose of 16/360 mg, and 4.8% at a dose of 32/360 mg

Stiffness: Arthritis-related stiffness can make it challenging to initiate movement, particularly after periods of inactivity, such as waking up in the morning

Lancet (2016) 387:67990